| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| antiœstrogène synthétique |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Gonadotropin-releasing hormone analog |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatostatin analogue-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely nafarelin (as nafarelin acetate) 200 microgram/1 actuation conventional release nasal spray (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing buserelin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buserelin 1mg/mL injection solution 5.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buserelin (as buserelin acetate) 100 microgram/actuation nasal spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Goserelin (as goserelin acetate) 3.6 mg prolonged-release subcutaneous implant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely goserelin (as goserelin acetate) 10.8 milligram/1 each prolonged-release subcutaneous implant (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 50micrograms/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 100micrograms/1mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 500micrograms/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 1mg/5mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 10mg depot injection+solvent (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 20mg powder and solvent for injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 30mg depot injection+solvent (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 3.75mg powder for injection solution + diluent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 11.25mg injection (pdr for recon)+diluent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing triptorelin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triptorelin 4.2mg powder and solvent for injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lanreotide-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lanreotide 30mg powder and solvent for injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing leuprorelin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buserelin 150micrograms spray (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Goserelin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Goserelin acetate preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing octreotide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing nafarelin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nafarelin acetate preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Histrelin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Histrelin acetate preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing synthetic hormone |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing somatostatin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 65mg implant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triptorelin 3.75mg powder and solvent for injection prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triptorelin 15mg powder and dilutent for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buserelin acetate [endometriosis] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprorelin acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lanreotide 60mg/0.3mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lanreotide 90mg/0.3mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lanreotide 120mg/0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Goserelin acetate 10.8mg injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 20mg depot injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 10mg (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 30mg (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nafarelin acetate 2mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nafarelin acetate 2mg/mL solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triptorelin pamoate 3.75mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triptorelin pamoate 11.25mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 15mg powder and solvent for injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 5mg/mL injection solution 0.2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 3.75mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 7.5mg/vial injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 22.5mg injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 30mg/vial injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 11.25mg powder for injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 1mg/mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 100mcg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 200mcg/mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 500mcg/mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide acetate 50mcg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Goserelin acetate 3.6mg implant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lanreotide acetate 30mg/vial injection suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Histrelin 120mcg/0.6mL (200mcg/mL peptide base) injection solution 0.6mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Histrelin 600mcg/0.6mL (1000mcg/mL peptide base) injection solution 0.6mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Histrelin 300mcg/0.6mL (500mcg/mL peptide base) injection solution 0.6mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| agent contraceptif |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Histrelin 50mg implant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Leuprolide acetate 45mg powder for injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Alfaprostol (substance) |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fenprostalene |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tetracosactide (substance) |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cyclofenil (substance) |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Octreotide 1mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Melanocyte stimulating hormone analog |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Poisoning caused by synthetic hormone substitute |
Causative agent (attribute) |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Ornipressin (substance) |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Medrogestone (substance) |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tetracosactide acetate |
Is a |
False |
Synthetic hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]